30 related articles for article (PubMed ID: 23551838)
1. External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.
Rusthoven CG; Carlson JA; Kavanagh BD
J Clin Oncol; 2015 Jun; 33(17):1987-8. PubMed ID: 25847937
[No Abstract] [Full Text] [Related]
2. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Vizziello D; Sun M; Karakiewicz PI; Menon M; Montorsi F; Briganti A
J Clin Oncol; 2014 Dec; 32(35):3939-47. PubMed ID: 25245445
[TBL] [Abstract][Full Text] [Related]
3. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
[TBL] [Abstract][Full Text] [Related]
4. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
5. Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.
Zuur LG; de Barros HA; van der Mijn KJC; Vis AN; Bergman AM; Pos FJ; van Moorselaar JA; van der Poel HG; Vogel WV; van Leeuwen PJ
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296924
[TBL] [Abstract][Full Text] [Related]
6. THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS.
Markić D; Oguić R; Krpina K; Vukelić I; Đorđević G; Žuža I; Španjol J
Acta Clin Croat; 2019 Nov; 58(Suppl 2):24-35. PubMed ID: 34975195
[TBL] [Abstract][Full Text] [Related]
7. Narrative review of management strategies and outcomes in node-positive prostate cancer.
D'Rummo KA; Chen RC; Shen X
Transl Androl Urol; 2021 Jul; 10(7):3176-3187. PubMed ID: 34430420
[TBL] [Abstract][Full Text] [Related]
8. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
10. Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.
Zareba P; Eastham J; Scardino PT; Touijer K
J Urol; 2017 Nov; 198(5):1077-1084. PubMed ID: 28625507
[TBL] [Abstract][Full Text] [Related]
11. Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.
Juloori A; Shah C; Stephans K; Vassil A; Tendulkar R
Prostate Cancer; 2016; 2016():2420786. PubMed ID: 27313896
[TBL] [Abstract][Full Text] [Related]
12. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.
Kalbasi A; Swisher-McClure S; Mitra N; Sunderland R; Smaldone MC; Uzzo RG; Bekelman JE
Cancer; 2014 Oct; 120(19):3089-96. PubMed ID: 24917426
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
16. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
17. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.
Zwergel U; Lehmann J; Wullich B; Schreier U; Remberger K; Zwergel T; Stoeckle M
J Urol; 2004 Mar; 171(3):1128-31. PubMed ID: 14767285
[TBL] [Abstract][Full Text] [Related]
18. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy.
Kaplan JR; Kowalczyk KJ; Borza T; Gu X; Lipsitz SR; Nguyen PL; Friedlander DF; Trinh QD; Hu JC
BJU Int; 2013 Jun; 111(8):1208-14. PubMed ID: 23551838
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
